New hope for advanced prostate cancer: extended targeted radiation trial opens
NCT ID NCT06531499
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 35 times
Summary
This study tests a longer course of a radioactive drug (lutetium-177) that targets prostate cancer cells. It is for adults with a specific type of advanced prostate cancer that has stopped responding to hormone therapy but who have not yet had chemotherapy. The goal is to see if giving up to 12 cycles is safe and how the radiation affects the body and tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Mayo Clinic Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nebraska Cancer Specialists
RECRUITINGOmaha, Nebraska, 68130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Novartis Investigative Site
RECRUITINGCologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
RECRUITINGWuppertal, North Rhine-Westphalia, 42283, Germany
-
Novartis Investigative Site
RECRUITINGAachen, 52074, Germany
-
Novartis Investigative Site
RECRUITINGBerlin, 13353, Germany
-
Novartis Investigative Site
RECRUITINGEssen, 45147, Germany
-
Novartis Investigative Site
RECRUITINGMünchen, 80377, Germany
-
Novartis Investigative Site
RECRUITINGRostock, 18057, Germany
-
Novartis Investigative Site
RECRUITINGNijmegen, Gelderland, 6500HB, Netherlands
-
Novartis Investigative Site
RECRUITINGSantiago Compostela, A Coruna, 15706, Spain
-
Novartis Investigative Site
RECRUITINGMajadahonda, Madrid, 28222, Spain
-
Novartis Investigative Site
RECRUITINGBarcelona, 08041, Spain
-
Novartis Investigative Site
RECRUITINGBellinzona, 6500, Switzerland
-
Novartis Investigative Site
RECRUITINGBern, 3010, Switzerland
-
Novartis Investigative Site
RECRUITINGSutton, Surrey, SM2 5PT, United Kingdom
-
Novartis Investigative Site
RECRUITINGBirmingham, West Midlands, B15 2TH, United Kingdom
-
Novartis Investigative Site
RECRUITINGGlasgow, G12 0YN, United Kingdom
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact
Contact Email: •••••@•••••
-
University of California LA
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Email: •••••@•••••
-
Wash U School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.